Also trades as: DRTSW (NASDAQ) · $vol 0M
DRTS NASDAQ
Alpha Tau Medical Ltd.
1W: +8.1%
1M: +31.7%
3M: +45.9%
YTD: +121.1%
1Y: +282.8%
3Y: +176.0%
5Y: +10.1%
$10.68
+0.65 (+6.48%)
Weekly Expected Move ±16.2%
$7
$9
$10
$12
$14
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$939.9M
52W Range2.81-10.85
Volume1,000,002
Avg Volume469,418
Beta1.12
Dividend—
Analyst Ratings
Company Info
CEOUzi Sofer
Employees125
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-08
Websitealphatau.com
5 Kiryat Hamada Street
Jerusalem 9777605
IL
Jerusalem 9777605
IL
972 3 577 4115
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest News
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau to Participate in May Investor Conferences
12 Health Care Stocks Moving In Monday's Intraday Session
Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 0 | — | 2026-03-18 | |
| Avruch Michael | 15,527 | $6.41 | 2026-03-18 | |
| KIDRON NADAV | 0 | — | 2026-03-18 |